	US 7,456,005 B2
	Modified xylanases exhibiting improved expression
Theresa White, Ottawa (Canada); Genevieve R. Giroux, Gloucester (Canada); and Katie E. A. Wallace, Nepean (Canada)
Assigned to Iogen Bio-Products Corporation, Ontario (Canada)
Filed on Mar. 25, 2005, as Appl. No. 11/88,725.
Claims priority of provisional application 60/556061, filed on Mar. 25, 2004.
Prior Publication US 2005/0214410 A1, Sep. 29, 2005
Int. Cl. C12N 9/24 (2006.01); C12N 15/74 (2006.01); C12N 1/18 (2006.01)

U.S. Cl. 435—200 [435/69.1; 435/74; 435/254.2; 435/278; 426/7; 536/23.2]

10 Claims

1. An isolated, modified Family 11 xylanase comprising, a functional consensus N-glycosylation site that is not found in a parental Family 11 xylanase from which the modified Family 11 xylanase is obtained, the modified Family 11 xylanase comprising nonnative asparagine at one or more of position 34 (X34N), position 131 (X131N), position 180 (X18ON), position 182 (X182N), the position number determined from sequence alignment of the modified Family 11 xylanase with the amino acid sequence of SEQ ID NO:1,

wherein the modified Family 11 xylanase, when expressed from a genetic construct comprising a promoter and a secretion signal in a Trichoderma host strain, exhibits an increase in expression efficiency of at least 40% when compared to the expression efficiency of said parental Family 11 xylanase expressed in a genetic construct with the same promoter and secretion signal.